Ọnwụnwa ụlọọgwụ ọhụrụ nke nyocha ọgwụ ọhụrụ maka ọgwụgwọ alopecia

Hope Medicine Inc., ụlọ ọrụ na-ahụ maka ụlọ ọgwụ na-emepụta biopharmaceutical ọhụrụ, ekwupụtala n'oge na-adịbeghị anya na US Food and Drug Administration (FDA) akwadola ngwa nyocha Ọhụụ Ọgwụ ọhụrụ (IND) maka ọmụmụ nke II iji nyochaa HMI-115, nke mbụ na klaasị. Ọgwụ mgbochi monoclonal na ọgwụgwọ androgen alopecia. Na 2021, HMI-115 enwetala US FDA Clearance of IND Application for Phase II clinical trial for the treatment of endometriosis.

Print Friendly, PDF & Email

N'April 2019, HopeMed banyere nkwekọrịta ikike pụrụiche zuru ụwa ọnụ na Bayer AG na mmepe na ịzụ ahịa nke mgbochi monoclonal mmadụ na-elekwasị anya na onye na-anabata PRL maka ọgwụgwọ nke ntutu isi nwoke na nwanyị, endometriosis, na ọrịa ndị ọzọ na-adịghị ala ala nwere prolactin dysregulated. (PRL) na-egosi. Ihe mgbochi a egosila ọmarịcha njirimara n'ụdị anụmanụ gụnyere ụdị NHP na ọmụmụ nchekwa mmadụ. Ọgwụgwọ ya maka ihe ngosi abụọ bụ isi, endometriosis na androgenetic alopecia, bụ ndị US FDA akwadola ha abụọ maka nnwale ụlọ ọgwụ Phase II. The Phase II clinical trial of HMI-115 na endometriosis ama butere ndebanye aha onye ọrịa na US site na njedebe nke 2021. Usoro ọgwụgwọ ya na-aga nke Abụọ maka ọgwụgwọ nke androgenetic alopecia bụ mba dị iche iche nke etiti, nke enweghị usoro, onye kpuru ìsì abụọ, placebo- ọmụmụ ihe a na-achịkwa, nke a na-eme atụmatụ ime na United States, Australia na mba ndị ọzọ.

Dr. Henri Doods, onye isi oche nke HopeMed, kwuru, "Enwere m mpako na FDA kwadoro IND nke abụọ anyị bụ ihe dị mkpa maka ụlọ ọrụ anyị na-eto eto. Ọ bụ nzọụkwụ dị mkpa maka ebumnuche anyị iweta ndị ọrịa mbụ na klaasị na ngwaahịa dị iche iche. Ma endometriosis na alopecia bụ ihe na-egosi ebe ndị ọrịa na-echesi ike maka nhọrọ ọgwụgwọ ọhụrụ yana nrụpụta ọrụ na nchekwa dị mma. Ọganihu nke ịnweta nkwenye IND abụọ n'ime obere oge dị otú ahụ bụ agbamume maka otu ahụ dum. Anyị na-agba mbọ na-emekwu ike na ịgbasa ihe omume R&D anyị iji wetara ndị ọrịa nhọrọ ọgwụgwọ ọhụụ ọhụrụ.

 

Print Friendly, PDF & Email

Banyere chepụtara

nchịkọta akụkọ

Onye nchịkọta akụkọ nke eTurboNew bụ Linda Hohnholz. Ọ dabere na eTN HQ na Honolulu, Hawaii.

Ahapụ a Comment